Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Assets for 4 consecutive years, with $11.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 76.23% to $11.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.5 million, a 76.23% increase, with the full-year FY2024 number at $6.5 million, down 20.77% from a year prior.
  • Assets was $11.5 million for Q3 2025 at bioAffinity Technologies, up from $4.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $14.1 million in Q3 2022 to a low of $4.8 million in Q2 2025.
  • A 4-year average of $8.7 million and a median of $8.2 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: plummeted 35.7% in 2024, then skyrocketed 76.23% in 2025.
  • bioAffinity Technologies' Assets stood at $12.2 million in 2022, then plummeted by 32.51% to $8.2 million in 2023, then decreased by 20.77% to $6.5 million in 2024, then skyrocketed by 77.26% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Assets are $11.5 million (Q3 2025), $4.8 million (Q2 2025), and $5.5 million (Q1 2025).